Skip to main content
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity
Published Web Location
http://europepmc.org/articles/PMC3922392?pdf=renderNo data is associated with this publication.
Abstract
Oral atorvastatin has prevented or reversed paralysis in the multiple sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE), and reduced development of new MS lesions in clinical trials. Besides inhibiting development of encephalitogenic T c
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.